Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma(†)

OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawai, Akira, Araki, Nobuhito, Naito, Yoichi, Ozaki, Toshifumi, Sugiura, Hideshi, Yazawa, Yasuo, Morioka, Hideo, Matsumine, Akihiko, Saito, Kenichi, Asami, Shun, Isu, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943671/
https://www.ncbi.nlm.nih.gov/pubmed/28173193
http://dx.doi.org/10.1093/jjco/hyw175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943671/
https://www.ncbi.nlm.nih.gov/pubmed/28173193
http://dx.doi.org/10.1093/jjco/hyw175

Ejemplares similares